PRNewsWire
01 Jun 2026, 09:28 UTC · 1h ago
Source · https://www.prnewswire.com/news-releases/goss-deadline-alert-hagens-berman-alerts-gossamer-bio-goss-investors-to-todays-lead-plaintiff-deadline-in-securities-class-action-302786572.html
Read source
Search tags
Story key points
3 claims · impact-rated
Gossamer Bio's Phase 3 PROSERA study for seralutinib failed to meet its primary endpoint for treating pulmonary arterial hypertension. — The failure of a Phase 3 trial for a potential first-in-class therapeutic eliminates a major growth catalyst and direct revenue path.
-1.00Gossamer Bio is currently not meeting the $1 minimum bid price required for continued listing on the Nasdaq Global Select Market. — Potential delisting increases volatility and liquidity risk, often triggering further sell-offs from institutional investors.
-0.70A securities class action lawsuit has been filed against Gossamer Bio alleging the company misled investors regarding the PROSERA trial design and patient recruitment. — Legal proceedings create additional financial liabilities and reputational damage, further depressing investor confidence.
-0.50Ticker attribution
Continue reading
6 related stories
Model heads
The company faces a securities class action lawsuit following a failed Phase 3 clinical trial and an 80% drop in stock price.
Merck is mentioned only as a reference for a successful study in a different trial.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
3h ago
